Background: Low serum 25-hydroxyvitamin D [25(OH)D] concentrations during pregnancy have been associated with adverse pregnancy outcomes in a few studies but not in other studies. Objectives: We assessed the serum 25(OH)D concentration at 10-14 wk of pregnancy and its association with adverse pregnancy outcomes and examined the predictive accuracy. Design: In this nested case-control study, we measured serum 25(OH)D in 5109 women with singleton pregnancies who were attending first-trimester screening in New South Wales, Australia. Multivariate logistic regression was conducted to examine the association between low 25(OH)D concentrations and adverse pregnancy outcomes (small for gestational age, preterm birth, preeclampsia, gestational diabetes, miscarriage, and stillbirth). The predictive accuracy of models was assessed. Results: The median (IQR) 25(OH)D concentration for the total population was 56.4 nmol/L (43.3-69.8 nmol/L). Serum 25(OH)D concentrations showed significant variation by parity, smoking, weight, season of sampling, country of birth, and socioeconomic status. After adjustment for maternal and clinical risk factors, low 25(OH)D concentrations were not associated with most adverse pregnancy outcomes. The area under the receiver operating characteristic curve (AUC) and likelihood ratio for a composite of severe adverse pregnancy outcomes of 25(OH)D concentrations ,25 nmol/L were 0.51 and 1.44, respectively, and, for risk factors alone, were 0.64 and 2.87, respectively. The addition of 25(OH)D information to maternal and clinical risk factors did not improve the ability to predict severe adverse pregnancy outcomes (AUC: 0.64; likelihood ratio: 2.32; P = 0.39). Conclusion: Low 25(OH)D serum concentrations in the first trimester of pregnancy are not associated with adverse pregnancy outcomes and do not predict complications any better than routinely assessed clinical and maternal risk-factor information.
INTRODUCTION
The prevalence and significance of vitamin D deficiency during pregnancy has attracted much recent public health interest. The main function of vitamin D is to maintain normal ranges of serum calcium and phosphorus by enhancing calcium absorption from the intestine and promoting the mobilization of calcium and other minerals from the skeleton (1) . Vitamin D also has immunomodulatory roles during pregnancy that enables successful implantation and stimulates antimicrobial activity (2) . From early in pregnancy, there are high demands for calcium to support both maternal calcium homeostasis and fetal skeletal development and growth (2) .
The definition and terminology used to describe adequate concentrations of vitamin D have been inconsistent. A recent Institute of Medicine report recommended serum 25-hydroxyvitamin D [25(OH)D] 4 concentrations .50 nmol/L for adequate bone health (3) , but clinical guidelines from The Endocrine Society have defined vitamin D deficiency and insufficiency as serum concentrations ,50 and 50-72.5 nmol/L, respectively (4) . The National Institute for Health and Clinical Excellence guidelines (5) define 25(OH)D concentrations ,25 nmol/L as insufficient, whereas other researchers (6) have proposed that 25(OH)D concentrations ,37.5 nmol/L are associated with lower bone mass density and increased risk of fracture. These definitions refer to the general population, are not universally accepted, and are not specific to pregnancy populations. In addition to the increased physiologic demands in pregnancy, geographical, or ethnic differences in 25(OH)D concentrations have suggested the important need to establish locally determined population reference ranges and normative concentrations during pregnancy (7) .
Studies that reported the association between 25(OH)D concentrations in early pregnancy and adverse pregnancy outcomes have been conflicting. Some studies reported low 25(OH)D concentrations were associated with increased risk of preeclampsia (8) , small for gestational age (SGA) (9) (10) (11) , gestational diabetes (GD) (12, 13) , and miscarriage (14) , whereas other studies have not reported a significant association with pregnancy complications (14) (15) (16) (17) (18) (19) (20) (21) (22) . However these studies had limitations including a small sample size, limited generalizability because of low response rates, or no information on several pregnancy outcomes. To our knowledge, no large study has assessed these associations. Furthermore, there is no information about the predictive accuracy of low 25(OH)D concentrations in early pregnancy in identifying pregnancies at risk. First-trimester screening provides an ideal opportunity for the early identification of pregnancies at risk. The aims of this study were 3-fold as follows: 1) describe normative concentrations of serum 25(OH)D in the first trimester of pregnancy, 2) examine the association between maternal 25(OH)D and risk of adverse pregnancy outcomes, and 3) assess the diagnostic accuracy of low 25(OH)D in predicting adverse pregnancy outcomes.
SUBJECTS AND METHODS

Participants and study design
A nested case-control study was conducted on the basis of a study population of 11,358 women who were attending firsttrimester Down syndrome screening between October 2006 and September 2007 in New South Wales (NSW), Australia. Data from banked serum and routinely collected electronic health databases were used. Serum samples were collected by the Pacific Laboratory Medicine Services, archived, and stored at 2808C. During this period, this was the state's only public screening service and received samples from throughout NSW. Serum samples were stored according to the time of collection in boxes that contained 81 samples in 9 3 9 rows. Cases of each study outcome of interest (SGA, preterm birth, preeclampsia, GD, miscarriage, and stillbirth) were randomly selected from the maternal screening population by using a computerized randomnumber function, with the specific box and row of the case identified. Controls were then sourced by using the remaining 8 samples in each row, regardless of their outcome status. Controls were selected by laboratory technicians from the relevant box that contained the case and who analyzed the full row (9 samples) unaware of the case's position within the row. This method ensured the random selection of samples, allowed laboratory technicians to remain blinded to pregnancy outcomes, and increased the efficiency of processing. One-half of cases from the study population were initially selected, but in the end, 63% of cases were identified because some samples in the control group were cases of other adverse pregnancy outcomes.
Biochemical analysis
Serum samples were thawed once, and serum concentrations of 25(OH)D were measured by using an automated immunoassay system (LIAISON; DiaSorin SpA). Intraassay and interassay CVs were ,9.5%, and the reported analytic sensitivity of the immunoassay was 4.9-368 nmol/L. Commonly used cutoffs to define 25(OH)D status were assigned at ,15, ,25, ,37.5, ,50, and ,75 nmol/L (4-6).
Data sources
Maternal information for archived serum samples were derived from the laboratory database, and corresponding pregnancy and birth outcomes were ascertained via record-linkage to the Perinatal Data Collection (PDC) and Admitted Patient Data Collection (APDC). The PDC is a statutory surveillance system of all births in NSW of $400 g birth weight or $20 wk of gestation; the PDC includes information on maternal demographic, pregnancy, delivery factors, and infant outcomes. The APDC is a census of all in-patient hospital admissions from NSW public and private hospitals, with records for both mothers and live-born infants. Relevant diagnoses are recorded for each admission and coded according to the International Classification of Diseases version 10-Australian Modification. Validation studies of the PDC and the APDC showed an excellent level of agreement with medical records and low rates of missing data (23, 24) . The reporting in both datasets have had high specificity (.99%), which indicated few false-positive reports. Only factors and outcomes accurately reported in birth or hospital data were included in analyses (25) . Record linkage was conducted by the NSW Centre for Health Record Linkage with identifying information removed before the release of data for analysis. The study was approved by the NSW Population and Health Services Research Ethics Committee.
Study outcomes assessed included SGA defined as birth weight ,10th and ,3rd percentiles of distribution for gestational age and infant sex (26) ; preterm birth at ,37 wk of gestation and very preterm birth ,34 wk of gestation; and early-onset and all preeclampsia, GD, miscarriage, and stillbirth. During the study period, preeclampsia was defined as the onset of hypertension (systolic blood pressure $140 mm Hg or diastolic blood pressure $90 mm Hg) from 20 wk of gestation accompanied by proteinuria (27) and early-onset preeclampsia classified for women that required delivery at #34 wk of gestation. GD was characterized as a fasting glucose concentration $5.5 mmol/L or 2-h plasma glucose concentration $8.0 mmol/L (28) . Information on preeclampsia and GD was obtained from both APDC and PDC data to maximize ascertainment. Preeclampsia (regardless of severity) and GD were determined if either the box was checked in the PDC record or any APDC record had a diagnosis in any of the 55 fields of gestational hypertension (International Classification of Diseases version 10-Australian Modification: O13 and O16), preeclampsia (O11 and O14), or eclampsia (O15) (for preeclampsia) and GD (O24) (29, 30) . Miscarriage was defined as spontaneous fetal loss between 10 and 20 wk of gestation and identified from APDC data (O00, O01, O02, O03, O05, or O06), whereas stillbirth was classified for spontaneous fetal death after 20 wk of gestation and was identified from PDC data. A composite of severe adverse pregnancy outcome variables was also developed that comprised the occurrence of either SGA less than the third percentile, preterm birth ,34 wk of gestation, early-onset preeclampsia, or stillbirth. Controls were defined as pregnancies unaffected by each outcome.
The key maternal and clinical risk factors used in this analysis included maternal age and weight (in kg) calculated at the time of first-trimester screening, parity (nulliparae or multiparae), smoking during pregnancy, any previously diagnosed hypertension (chronic or pregnancy) or diabetes (pregestational or gestational), season at sampling, country of birth, and socioeconomic disadvantage. The season of sample collection (Southern Hemisphere) was defined as spring (September to November), summer (December to February), autumn (March to May), and winter (June to August). Socioeconomic disadvantage was determined by using the Socioeconomic Indexes for Areas relative disadvantage scores developed by the Australian Bureau of Statistics (31) and categorized into quintiles. Maternal weight was missing in 831 records (16.3%). Multiple imputation was used to account for the missing maternal weight, which is a technique that predicts missing values by using existing values from other variables (32) . The following other missing data were infrequent and excluded from the analyses: maternal age was missing in one record (0.002%), smoking status was missing in 42 records (0.8%), country of birth was missing in in 6 records (0.1%), and socioeconomic disadvantage information was missing in 13 records (0.25%).
Statistical analysis
Because each case and control had a known probability of selection calculated as the prevalence of each pregnancy outcome, concentrations of 25(OH)D were weighted to account for sampling probabilities to determine normative concentrations for our pregnancy sample. The weight calculation involved the multiplication of each case and control by using the inverse proportion of the probability of selection. The 25(OH)D distribution was calculated by applying individual weights. Similarly, to ensure comparability with the NSW state maternity population, we weighted all observations for population rates of age, parity, smoking, and socioeconomic disadvantage by using Socioeconomic Indexes for Areas quintiles (33) .
Normative concentrations in the overall population and by maternal characteristics were examined at various percentiles (ie, 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentiles), and differences were assessed by using the Kruskal-Wallis test. Spearman's coefficient was used to determine correlations between 25(OH)D and maternal weight. A comparison of maternal characteristics and concentrations of 25(OH)D between women with and without each study outcome was performed by using a contingency table, Student's t test, or Wilcoxon's rank sum test for categorical, normal, or nonnormally distributed data, respectively. A conditional univariate and multivariate logistic regression analysis was performed to assess crude and adjusted association between low 25(OH)D and adverse pregnancy outcomes and taking into account important maternal and clinical risk factors in the latter analysis.
In the assessment of the predictive accuracy, we defined low 25(OH)D concentrations at ,25 and ,37.5 nmol/L. The performance in predicting severe pregnancy outcomes in the total population and a group of women at high risk (weight .85 kg or born in countries in which they were most likely to have dark skin or be covered) was determined by examining the AUC derived from logistic regression models. AUC results were also examined to determine whether models performed better than chance (0.5). Models for 25(OH)D alone, models including maternal and clinical risk factors only, and models with 25(OH)D and risk factors combined were compared. A comparison of the predictive accuracy of models was performed by evaluating maximum likelihood estimates and applying the likelihood ratio (chi-square) test. Finally, estimates of predictive accuracy were calculated including sensitivity, specificity, positive values, negative predictive values, and the positive likelihood ratio with the exact binominal CI. P , 0.05 was considered statistically significant, and analyses were performed with SAS 9.2 software (SAS Institute Inc).
RESULTS
A total of 5762 serum samples were tested for 25(OH)D, with linked health information relevant to the pregnancy available for 5397 women (93.7%). We excluded 288 women whose blood samples were taken before 10 or after 14 wk of gestation, who had 25(OH)D concentrations that were outside limits of the assay detection, or who had a medical abortion, a twin pregnancy, or an infant with a major congenital anomaly. A total of 5109 women were included in the analysis. Demographic characteristics and percentile distributions of serum 25(OH)D concentrations are presented in Table 1 . The median (IQR) serum concentration of 25(OH)D for the total population was 56.4 nmol/L (43.4-69.9 nmol/L); 294 women (5.8%) had serum concentrations ,25 nmol/L, 835 women (16.3%) had serum concentrations ,37.5 nmol/L, and 999 (19.6%) had serum concentrations .75 nmol/L. Women who had a first baby; smoked during pregnancy; were born in Middle Eastern, Asian, African, or Caribbean countries; or were living in socially disadvantaged areas had lower 25(OH)D concentrations (P , 0.05). There was a negative correlation with maternal weight (r = 20.36, P = 0.01) ( Table 1 ). There was also a significant variation by season of sampling (P , 0.001). Concentrations of 25(OH)D were highest in the autumn (median: 63.5 nmol/L; IQR: 52.0-78.4 nmol/L) and lowest in the winter (median: 51.5 nmol/L; IQR: 37.5-64.4 nmol/L) (P , 0.001) ( Figure 1) .
Maternal characteristics and 25(OH)D serum concentrations by adverse pregnancy outcomes are shown in Table 2 . In comparison with unaffected pregnancies (median: 56.9 nmol/L; IQR: 43.9-70.8 nmol/L), median concentrations of 25(OH)D in the first trimester were lower for women diagnosed with GD (median: 52.1 nmol/L; IQR: 41.5-63.6 nmol/L; P , 0.001). The association between 25(OH)D and adverse pregnancy outcomes is presented in Table 3 . After adjustment for risk factors, women with 25(OH)D concentrations ,25 nmol/L had increased risk of having an SGA ,10th-percentile infant (adjusted OR: 1.58; 95% CI: 1.06, 2.35). In the univariate analysis, women with 25(OH)D concentrations ,37.5 nmol/L had increased risk of GD; however, this association was attenuated after adjustment for maternal factors (adjusted OR: 1.08; 95% CI: 0.74, 1.56). Women with low 25(OH)D concentrations had a tendency toward increased risk of spontaneous preterm birth (P = 0.09) or a severe pregnancy outcome (P = 0.07) but reduced risk of preeclampsia (P = 0.07) ( Table 3 ). There was also a slight tendency for high 25(OH)D concentrations .75 nmol/L to be protective against early-onset preeclampsia (P = 0.09); however, numbers were small, and results were imprecise. There was no association between women with low 25(OH)D concentrations and any other adverse pregnancy outcome ( Table 3) , regardless of the various cutoffs applied (data not presented). In particular, there was no relation between 25(OH)D concentrations ,15 nmol/L and the composite measure of any adverse pregnancy outcome (adjusted OR: 1.20; 95% CI: 0.69, 2.07) (data not included in tables). When the association between 25(OH)D concentrations and severe adverse pregnancy outcomes was analyzed in a subgroup of high-risk women (n = 758), the adjusted OR for concentrations ,25 and ,37.5 nmol/L was 2.34 (95% CI: 1.01, 5.50) and 2.42 (95% CI: 1.20, 4.92), respectively. In absolute terms, #11 in 100 women with 25(OH)D ,37.5 nmol/L compared with #6 in 100 women without low 25(OH)D had a severe adverse pregnancy outcome.
Predictive accuracy results for severe adverse pregnancy outcomes are shown in Table 4 . The AUC of the univariate model was not different from chance, and the predictive accuracy of previous risk factors was poor. The addition of 25(OH)D information to maternal and clinical risk factors did not improve the ability to predict adverse pregnancy outcomes (chi-square = 0.75, P = 0.39). When the analysis was restricted to women at high risk of low 25(OH)D, the predictive accuracy of 25(OH)D alone was inferior compared with information from maternal and clinical history risk factors (chi-square = 0.96, P = 0.33) ( Table 4 ).
DISCUSSION
To our knowledge, this is the largest study to examine maternal vitamin D concentrations in women in first trimester and assess the association with adverse pregnancy outcomes. Our results indicated that there is variation in serum 25(OH)D concentrations in first trimester by a range of maternal characteristics and season. In general, low 25(OH)D concentrations were not associated with most adverse pregnancy outcomes, although women at high risk, such as those overweight or from Middle Eastern and Asian countries, were more likely to develop a severe outcome. Despite this effect, on additional analyses, our findings revealed that low 25(OH)D concentrations did not predict complications any better than did routinely collected maternal and clinical risk-factor information, even when analyses were limited to these high risk women. Overall, our findings suggested that routine screening for 25(OH)D concentrations in early pregnancy would not help to predict pregnancies at risk of adverse pregnancy outcomes. These data also supported recent Australian Government antenatal care clinical practice guidelines that only recommended 25(OH)D testing of pregnant women at high risk of vitamin D deficiency (34) . Our results provided important information and a moderating message for the current enthusiasm for screening and vitamin D supplemention in pregnancy (35) . Support for vitamin D testing and supplementation has been based on certain studies that suggested low 25(OH)D concentrations are associated with potential harms in pregnancy (8) (9) (10) (11) (12) (13) . However, a recent randomized trial of vitamin D supplementation in pregnancy has suggested that there is no impact or decrease on adverse pregnancy outcomes, including preeclampsia, GD, and fetal growth (36) . Despite not having information regarding vitamin D supplementation in women, screening and supplementation were uncommon during the study period. Since then, vitamin D testing in Australian women aged 15-44 y has increased .13-fold and with a significant cost to the public health care system of $31.8 million in 2011 (37) . Moreover, some studies have shown elevated maternal concentrations .75 nmol/L were associated with increased risk of SGA infants (9) , whereas our study did not show this association. The subsequent development of atopic eczema in the offspring has also been identified (38) . Although our study did not assess childhood health, the potential long-term effect of vitamin D supplementation on the mother and offspring is unknown.
Our study showed no significant association between low 25(OH)D concentrations and most adverse pregnancy outcomes and was consistent with the majority of previous studies (14) (15) (16) (17) (18) (19) (20) (21) (22) that assessed 25(OH)D in early pregnancy. Although we showed that women with 25(OH)D concentrations ,25 nmol/L were more likely to have an infant diagnosed SGA ,10th percentile, this result may have been a chance finding because of multiple testing given that the result was not replicated in infants SGA less than the third percentile, and results were imprecise. Other studies have evaluated 25(OH)D later in pregnancy when it may have been too late to intervene, and testing may provide no additional benefit. Only a few studies have reported increased risks for women tested in early pregnancy; 2 studies showed an association between 25(OH)D concentrations ,30 and ,37.5 nmol/L and SGA infants in white women (9, 11) , one study reported 5-fold increased risk of preeclampsia in white women with 25(OH)D concentrations ,37.5 nmol/L at ,22 wk of pregnancy (8) , and one study showed 2-fold risk of GD in women with 25(OH)D concentrations ,73.5 nmol/L at 15-18 wk of pregnancy (12) . Unique to our study, we assessed the predictive accuracy of low 25(OH)D concentrations for severe adverse pregnancy outcomes and showed that these were poor and also revealed that 25(OH)D adds very little information in addition to maternal risk factors.
The variation in findings between studies may also be explained by differences in cutoffs, population characteristics, and methods used to measure 25(OH)D concentrations. Cutoffs to define vitamin D sufficiency and insufficiency have been traditionally determined on the basis of the threshold above where 25(OH)D serum concentrations have no correlation with serum parathyroid hormone (PTH) concentrations (PTH plateau) (39) . A recent systematic review of 70 studies showed 25(OH)Dconcentration thresholds varied between 25 and 150 nmol/L (40) , which suggested a large individual variation. Therefore, the use of particular cutoffs to define vitamin D status may be unreliable because of this heterogeneity. Furthermore, a recent study showed no overall correlation between concentrations of PTH with 25(OH)D in pregnant women tested in the first trimester. The authors concluded that 25(OH)D-threshold estimates could not be precisely defined and are, therefore, less useful for determining the optimum vitamin D status during pregnancy (41) . In addition, studies have shown that genetic differences in vitamin D receptor has a strong influence on individual vitamin D metabolism that may have an impact on the susceptibility to disease (42) and low birth size in infants from 25(OH)D-deficient mothers (43) . Thus, future studies stratified by genetic variation are warranted. Significant population and geographic variation on the basis of latitude and ethnic background have also been shown in a recent review of serum concentrations of 25(OH)D in women during the first trimester (7) . Regional differences in 25(OH)D concentrations were confirmed when we compared our results (latitude 348S; median: 56.4 nmol/L) with those of a recent study that examined 25(OH)D concentrations in pregnant women before 20 wk of gestation who were living in tropical Australia (latitude: 16.98S), with a mean 25(OH)D concentration of 114 nmol/L and no women with concentrations ,50 nmol/L (44) . Therefore, our findings are relevant to sun-rich latitudes with a low prevalence of vitamin D deficiency and may not be applicable to other settings. In addition, maternal risk factors for low 25(OH)D concentrations in pregnancy such as obesity (because of the storage of vitamin D in fat) and ethnicity are also risk factors for preeclampsia and GD. Therefore, adjustment for such factors may not completely control for the dual effect that these can have on adverse pregnancy outcomes (45) . Finally, studies have shown a lack of standardization of methods of 25(OH)D measurement and significant variability in results between assay methods and laboratories (46, 47) .
Strengths of the study were the assessment of a large sample of pregnant women who were attending a first-trimester screening over 4 seasons. Record linkage of laboratory to birth and hospital data ensured the follow-up and ascertainment of pregnancy outcomes for 93% of samples with minimal missing information. Missing health and pregnancy information was mostly attributable to women who resided in bordering towns and gave birth in hospitals out of state, but these women had similar characteristics as those of women included in the study. Because of limited resources, we were unable to include all women who underwent first-trimester screening in our study and, thus, we conducted a nested case-control study instead. To overcome this potential limitation and ensure the representativeness of our sample, cases were randomly selected according to population prevalence rates, and corresponding controls were randomly identified on the basis of an unknown outcome status and matched by the timing of collection. Furthermore, we adjusted and weighted our results back to population rates of maternal characteristics to ensure comparability with the NSW maternity population. A possible weakness of the study was that outcomes were not verified with individual medical records, but we only used data in this study that were previously validated (25) . However, other potential confounders such as ethnicity, BMI, sun exposure, education, and lifestyle behavior were not measured or available in in data sets and could not be taken into account.
In conclusion, our findings confirm that there is a variation in 25(OH)D serum concentrations in first trimester by maternal characteristics and the season of testing. Low 25(OH)D concentrations were not associated an increased risk of most adverse pregnancy outcomes and have poor predictive accuracy. Results reveal that widespread screening for vitamin D deficiency in the first trimester of pregnancy would not efficiently identify women at risk of adverse pregnancy outcomes. Our findings suggest that current screening and testing for vitamin D in early pregnancy without taking into account individual variability lead to overdiagnosis and unnecessary and potentially harmful treatment of women and causes excessive burden and costs to health care providers. Obstet 2012;116:6-9. Severe pregnancy outcome was defined as a composite outcome of either small for gestational age less than the third percentile, preterm birth ,34 wk, early-onset preeclampsia, or stillbirth. LR (+), positive likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; 25(OH)D, 25-hydroxyvitamin D.
2
Test of AUC against chance (0.5) by using the likelihood ratio (chi-square) test.
3
Percentage; 95% CI in parentheses (all such values). 4 Maternal and clinical risk factors were as follows: maternal age, parity, smoking during pregnancy, maternal weight, previously diagnosed hypertension, previously diagnosed diabetes, season at sampling, country of birth, or socioeconomic disadvantage 5 Subanalysis in high-risk women (weight .85 kg or born in India, Pakistan, Bangladesh, Sri Lanka, the Middle East, or African countries) with severe pregnancy outcomes compared with high-risk women without severe pregnancy outcomes.
